Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 8/2011

01-05-2011 | Review Article

Pharmacotherapeutic Management of Locally Advanced Prostate Cancer

Current Status

Authors: Dr Jarad M. Martin, Stephane Supiot, Dominik R. Berthold

Published in: Drugs | Issue 8/2011

Login to get access

Abstract

Locally advanced prostate cancer (LAPC) is a heterogeneous entity usually embracing T3-4 and/or pelvic lymph-node-positive disease in the absence of established metastases. Outcomes for LAPC with single therapies have traditionally been poor, leading to the investigation of adjuvant therapies. Prostate cancer is a hormonally sensitive tumour, which usually responds to pharmacological manipulation of the androgen receptor or its testosterone-related ligands. As such, androgen deprivation therapy (ADT) has become an important adjuvant strategy for the treatment of LAPC, particularly for patients managed primarily with radiotherapy. Such results have generally not been replicated in surgical patients. With increased use of ADT has come improved awareness of the numerous toxicities associated with long-term use of these agents, as well as the development of strategies for minimizing ADT exposure and actively managing adverse effects. Several trials are exploring agents to enhance radiation cell sensitivity as well as the application of adjuvant docetaxel, an agent with proven efficacy in the metastatic, castrate-resistant setting. The recent work showing activity of cabazitaxel, sipuleucel-T and abiraterone for castrate-resistant disease in the post-docetaxel setting will see these agents investigated in conjunction with definitive surgery and radiotherapy.
Literature
1.
Sobin LH, Gospodarowicz MK, Wittekind C, et al. TNM classification of malignant tumours. Chichester: Wiley-Blackwell, 2010
2.
Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348(25): 2491–9PubMedCrossRef
3.
Schiavina R, Scattoni V, Castellucci P, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008; 54(2): 392–401PubMedCrossRef
4.
Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53(1): 68–80PubMedCrossRef
5.
May M, Knoll N, Siegsmund M, et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1,296 patients. J Urol 2007; 178(5): 1957–62; discussion 1962
6.
Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–23
7.
Cooperberg MR, Grossfeld GD, Lubeck DP, et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003; 95(13): 981–9PubMedCrossRef
8.
Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132(7): 566–77PubMed
9.
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102(11): 1531–8PubMedCrossRef
10.
Mcleod D, Zinner N, Tomera K, et al. A phase 3, multi-center, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58(5): 756–61PubMedCrossRef
11.
12.
Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294(2): 238–44PubMedCrossRef
13.
Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355(9214): 1491–8CrossRef
14.
Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164(5): 1579–82PubMedCrossRef
15.
Wirth MP, See WA, Mcleod DG, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172(5 I): 1865–70PubMedCrossRef
16.
Di Lorenzo G, Buonerba C, Autorino R, et al. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010; 70(8): 983–1000PubMedCrossRef
17.
Labrie F, Candas B, Gomez JL, et al. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 2002; 60(1): 115–9PubMedCrossRef
18.
Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 2001; 6(2): 177–82PubMedCrossRef
19.
Gleave ME, Sato N, Goldenberg SL, et al. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model. J Urol 1997; 157(5): 1727–30PubMedCrossRef
20.
Yee DS, Lowrance WT, Eastham JA, et al. Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. BJU Int 2010; 105(2): 185–90PubMedCrossRef
21.
Schulman CC, Debruyne FMJ, Forster G, et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol 2000; 38(6): 706–13PubMedCrossRef
22.
Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166(2): 500–6; discussion 506-7PubMedCrossRef
23.
Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002; 167(1): 112–6PubMedCrossRef
24.
Aus G, Abrahamsson PA, Ahlgren G, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002; 90(6): 561–6PubMedCrossRef
25.
Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170(3): 791–4PubMedCrossRef
26.
Labrie F, Cusan L, Gomez JL, et al. Neoadjuvant hormonal therapy: the Canadian experience. Urology 1997; 49 (3A Suppl.): 56–64PubMedCrossRef
27.
Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341(24): 1781–8PubMedCrossRef
28.
Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7(6): 472–9PubMedCrossRef
29.
Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360(9327): 103–6PubMedCrossRef
30.
Roach 3rd M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26(4): 585–91PubMedCrossRef
31.
D’Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299(3): 289–95PubMedCrossRef
32.
McLeod DG, Iversen P, See WA, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97(2): 247–54PubMedCrossRef
33.
Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61(5): 1285–90PubMedCrossRef
34.
Zagars GK, Johnson DE, Von Eschenbach AC, et al. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 1988; 14(6): 1085–91PubMedCrossRef
35.
Granfors T, Modig H, Damber JE, et al. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 2006; 176(2): 544–7PubMedCrossRef
36.
Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6(11): 841–50PubMedCrossRef
37.
Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11(11): 1066–73PubMedCrossRef
38.
Kumar S, Shelley M, Harrison C, et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006 (4): CD006019
39.
Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373(9660): 301–8PubMedCrossRef
40.
Warde P, Mason MD, Sydes M, et al. Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) [NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633]. J Clin Oncol 2010; 28: 959s
41.
Mottet N, Peneau M, Mazeron J-J, et al. Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer [abstract no. 4505]. J Clin Oncol 2010; 28: 15s
42.
Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8(7): 545–54PubMedCrossRef
43.
Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010; 28(7): 1106–11PubMedCrossRef
44.
Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer: who dies of disease? Int J Radiat Oncol Biol Phys 2010; 79(5): 1310–7PubMedCrossRef
45.
Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8(6): 475–87PubMedCrossRef
46.
Al-Mamgani A, Van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72(4): 980–8PubMedCrossRef
47.
Beckendorf V, Guerif S, Le Prise E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. Epub 2010 Dec 11
48.
Al-Mamgani A, Heemsbergen WD, Levendag PC, et al. Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiother Oncol 2010; 96(1): 13–8PubMedCrossRef
49.
Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74(5): 1405–18PubMedCrossRef
50.
Williams S, Buyyonouski M, Kestin L, et al. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose. Int J Radiat Oncol Biol Phys 2010; 79(3): 724–31PubMedCrossRef
51.
Martin JM, Rosewall T, Bayley A, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 69(4): 1084–9PubMedCrossRef
52.
Martin JM, Bayley A, Bristow R, et al. Image guided dose escalated prostate radiotherapy: still room to improve. Radiat Oncol 2009; 4: 50PubMedCrossRef
53.
Lawton CA, Desilvio M, Roach 3rd M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69(3): 646–55PubMedCrossRef
54.
Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26(15): 2497–504PubMedCrossRef
55.
Crook J, Ludgate C, Malone S, et al. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73(2): 327–33PubMedCrossRef
56.
Bolla M, De Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360(24): 2516–27PubMedCrossRef
57.
Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12(5): 451–9PubMedCrossRef
58.
Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50(5): 1243–52PubMedCrossRef
59.
Pollack A, Salem N, Ashoori F, et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys 2001; 51(4): 1002–7PubMedCrossRef
60.
Kaminski JM, Hanlon AL, Joon DL, et al. Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys 2003; 57(1): 24–8PubMedCrossRef
61.
Zietman AL, Prince EA, Nakfoor BM, et al. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997; 38(5): 1067–70PubMedCrossRef
62.
Alonzi R, Padhani AR, Taylor NJ, et al. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys. Epub 2010 Jul 12
63.
Milosevic M, Chung P, Parker C, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 2007; 67(13): 6022–5PubMedCrossRef
64.
Harrington C, Campbell G, Wynne C, et al. Randomised, placebo-controlled, crossover trial of sildenafil citrate in the treatment of erectile dysfunction following external beam radiation treatment of prostate cancer. J Med Imaging Radiat Oncol 2010; 54(3): 224–8PubMedCrossRef
65.
Irani J, Salomon L, Oba R, et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010; 11(2): 147–54PubMedCrossRef
66.
Levine GN, D’amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010; 121(6): 833–40PubMedCrossRef
67.
Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181(5): 1998–2006; discussion 2007-1998PubMedCrossRef
68.
Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352(2): 154–64PubMedCrossRef
69.
Holmes-Walker DJ, Woo H, Gurney H, et al. Maintaining bone health in patients with prostate cancer. Med J Aust 2006; 184(4): 176–9PubMed
70.
Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 2009; 24 Suppl. 2: S389–94PubMedCrossRef
71.
Walker LM, Robinson JW. The unique needs of couples experiencing androgen deprivation therapy for prostate cancer. J Sex Marital Ther 2010; 36(2): 154–65PubMedCrossRef
72.
Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006; 60(3): 201–15PubMedCrossRef
73.
Nelson CJ, Lee JS, Gamboa MC, et al. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008; 113(5): 1097–106PubMedCrossRef
74.
Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90(12): 6410–7PubMedCrossRef
75.
Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004; 100(5): 892–9PubMedCrossRef
76.
Morote J, Orsola A, Abascal JM, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 2006; 175(5): 1679–83; discussion 1683PubMedCrossRef
77.
Sieber PR, Keiller DL, Kahnoski RJ, et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171 (6 Pt 1): 2272–6, quiz 2435PubMedCrossRef
78.
Smith MR, Goode M, Zietman AL, et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004; 22(13): 2546–53PubMedCrossRef
79.
Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175(1): 136–9; discussion 139PubMedCrossRef
80.
Dickman PW, Adolfsson J, Astrom K, et al. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol 2004; 172 (6 Pt 1): 2208–12PubMedCrossRef
81.
Alibhai SM, Duong-Hua M, Cheung AM, et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 2010; 184(3): 918–23PubMedCrossRef
82.
Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345(13): 948–55PubMedCrossRef
83.
Israeli RS, Rosenberg SJ, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007; 5(4): 271–7PubMedCrossRef
84.
Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146(6): 416–24PubMed
85.
Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361(8): 745–55PubMedCrossRef
86.
Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63(4): 742–5PubMedCrossRef
87.
Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24(24): 3979–83PubMedCrossRef
88.
Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003; 104(2): 195–201CrossRef
89.
Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995; 154(1): 100–4PubMedCrossRef
90.
Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91(4): 1305–8PubMedCrossRef
91.
Keating NL, O’Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102(1): 39–46PubMedCrossRef
92.
Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24(27): 4448–56PubMedCrossRef
93.
Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110(7): 1493–500PubMedCrossRef
94.
Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27(21): 3452–8PubMedCrossRef
95.
D’amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25(17): 2420–5PubMedCrossRef
96.
Nguyen PL, Chen MH, Beard CJ, et al. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys 2010; 77(4):1046–52PubMedCrossRef
97.
Jordan Jr WP, Blackard CE, Byar DP. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 1977; 70(12): 1411–3PubMed
98.
The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79(2): 235–46CrossRef
99.
Schroder FH, Kurth KH, Fossa SD, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009; 55(1): 14–22PubMedCrossRef
100.
Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24(12): 1868–76PubMedCrossRef
101.
Studer UE, Hauri D, Hanselmann S, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004; 22(20): 4109–18PubMedCrossRef
102.
Verhagen PC, Schroder FH, Collette L, et al. Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 2010; 58(2): 261–9PubMedCrossRef
103.
Akakura K, Bruchovsky N, Goldenberg SL, et al. Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate-specific antigen. Cancer 1993; 71(9): 2782–90PubMedCrossRef
104.
Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. Journal of Steroid Biochemistry and Molecular Biology 1996; 58(2): 139–46PubMedCrossRef
105.
Abrahamsson PA. Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature. Eur Urol 2010; 57(1): 49–59PubMedCrossRef
106.
Malone S, Perry G, Segal R, et al. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU Int 2005; 96(4): 514–20PubMedCrossRef
107.
Shaw GL, Wilson P, Cuzick J, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 2007; 99(5): 1056–65PubMedCrossRef
108.
Calais Da Silva FEC, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55(6): 1269–77PubMedCrossRef
109.
Klotz L, O’Callaghan CJ, Ding K, et al. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013 [abstract no. 3]. J Clin Oncol 2011: 29 Suppl. 7 Available from URL: http://​www.​asco.​org [Accessed 2011 Mar 9]
110.
De Leval J, Boca P, Youssef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: Results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002; 1(3): 163–71PubMedCrossRef
111.
Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 2006; 24(24): 3984–90PubMedCrossRef
112.
Langenhuijsen JF, Schasfoort EMC, Heathcote P. Intermittent androgen suppression in patients with advanced prostate cancer: an update of the TULP survival data. 23rd Annual Congress of the European Association of Urology; 2008 Mar 26–29; Milan
113.
Tunn UW, Kurek R, Kienle E. Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy [abstract 1458]. J Urol 2004; 171: 384CrossRef
114.
Verhagen PCMS, Wissenburg LD, Wildhagen MF. Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer. 23rd Annual Congress of the European Association of Urology; 2008 Mar 26–29; Milan
115.
Seruga B, Tannock IF. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 2008; 5(10): 574–6PubMedCrossRef
116.
Gleave M, Klotz L, Taneja SS. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol 2009; 27(1): 81–6
117.
Tombal B. Intermittent Androgen Deprivation Therapy: Conventional Wisdom versus Evidence. Eur Urol 2009; 55(6): 1278–80PubMedCrossRef
118.
119.
Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26(2): 242–5PubMedCrossRef
120.
Sonpavde G, Sternberg CN. Neoadjuvant systemic therapy for urological malignancies. BJU Int 2010; 106(1): 6–22PubMedCrossRef
121.
Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63(6): 1138–42PubMedCrossRef
122.
Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11(14): 5233–40PubMedCrossRef
123.
Garzotto M, Higano CS, O’Brien C, et al. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 2010; 116(7): 1699–708PubMedCrossRef
124.
Chi KN, Chin JL, Winquist E, et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008; 180(2): 565–70; discussion 570PubMedCrossRef
125.
Cancer and Leukemia Group B. Surgery with or without docetaxel and leuprolide or goserelin in treating patients with high-risk localized prostate cancer [ClinicalTrials.gov identifier NCT00430183]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 Apr 26]
126.
Federation Nationale des Centres de Lutte Contre le Cancer. Hormone therapy with or without docetaxel and estramustine in treating patients with prostate cancer that is locally advanced or at high risk of relapse [ClinicalTrials.gov identifier NCT00055731]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 Apr 26]
127.
De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376(9747): 1147–54PubMedCrossRef
128.
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5): 411–22PubMedCrossRef
129.
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21): 1995–2005PubMedCrossRef
130.
Scandinavian Prostate Cancer Group. Docetaxel compared with observation in treating patients who have undergone radical prostatectomy for prostate cancer [ClinicalTrials.gov identifier NCT00376792]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 Apr 26]
131.
Department of Veterans Affairs. Chemotherapy after prostatectomy (CAP) for high risk prostate carcinoma [ClinicalTrials.gov identifier NCT00132301]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 Apr 26]
132.
Sanofi-Aventis. Adjuvant leuprolide with or without docetaxel in high risk prostate cancer after radical prostatectomy [ClinicalTrials.gov identifier NCT00283062]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 Apr 26]
133.
Flaig TW, Tangen CM, Hussain MH, et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008; 26(9): 1532–6PubMedCrossRef
134.
Bromfield GP, Meng A, Warde P, et al. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis 2003; 6(1): 73–85PubMedCrossRef
135.
Supiot S, Shubbar S, Fleshner N, et al. A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. Radiother Oncol 2008; 88(1): 53–60PubMedCrossRef
136.
Kovalenko OA, Kaplunov J, Herbig U, et al. Expression of (NES-)hTERT in cancer cells delays cell cycle progression and increases sensitivity to genotoxic stress. PLoS One 2010; 5(5): e10812PubMedCrossRef
137.
Camphausen K, Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of gamma-H2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004; 64(1): 316–21PubMedCrossRef
138.
George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7(7): 1932–6PubMed
139.
Abdollahi A, Griggs DW, Zieher H, et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances anti-angiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11(17): 6270–9PubMedCrossRef
140.
Fenton BM, Paoni SF. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res 2007; 67(20): 9921–8PubMedCrossRef
141.
Timke C, Zieher H, Roth A, et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008; 14(7): 2210–9PubMedCrossRef
142.
Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006; 66(20): 10040–7PubMedCrossRef
143.
Parker C, Milosevic M, Toi A, et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58(3): 750–7PubMedCrossRef
144.
Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008; 9(4): 342–51PubMedCrossRef
145.
146.
Palayoor ST, Mitchell JB, Cerna D, et al. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer 2008; 123(10): 2430–7PubMedCrossRef
147.
Meng AX, Jalali F, Cuddihy A, et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 2005; 76(2): 168–76PubMedCrossRef
148.
Chan N, Bristow RG. “Contextual” synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res 2010;16(18): 4553–60PubMedCrossRef
149.
Liu SK, Coackley C, Krause M, et al. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 2008; 88(2): 258–68PubMedCrossRef
150.
Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009; 9(10): 714–23PubMed
151.
Choudhury A, Cuddihy A, Bristow RG. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 2006; 16(1): 51–8PubMedCrossRef
152.
Choudhury A, Zhao H, Jalali F, et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther 2009; 8(1): 203–13PubMedCrossRef
153.
Deutsch E, Maggiorella L, Eschwege P, et al. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol 2004; 5(5): 303–13PubMedCrossRef
154.
Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: yes or no? Cancer Metastasis Rev 2004; 23(3–4): 237–57PubMedCrossRef
155.
Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8(3): 282–8PubMedCrossRef
156.
Supiot S, Zhao H, Wiman K, et al. PRIMA-1(met) radio-sensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol 2008; 86(3): 407–11PubMedCrossRef
157.
Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420(1): 25–7PubMedCrossRef
158.
Khor LY, Bae K, Paulus R, et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 2009; 27(19): 3177–84PubMedCrossRef
159.
Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008; 7(4): 993–9PubMedCrossRef
160.
Gutt R, Tonlaar N, Kunnavakkam R, et al. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010; 28(16): 2653–9PubMedCrossRef
161.
Kollmeier MA, Katz MS, Mak K, et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2010; 79(3): 713–8PubMedCrossRef
162.
Kaneta S, Satoh K, Kano S, et al. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 2003; 170(2): 237–43PubMedCrossRef
163.
Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9(1): 10–9PubMed
164.
Farwell WR, D’Avolio LW, Scranton RE, et al. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst. Epub 2011 Apr 15
165.
Carles J, Nogue M, Sole JM, et al. Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010; 76(4): 1085–91PubMedCrossRef
166.
Rathkopf D, Wong BY, Ross RW, et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010; 66(1): 181–9PubMedCrossRef
167.
Di Lorenzo G, Tortora G, D’armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8(11): 3438–44PubMed
168.
Schlomm T, Kirstein P, Iwers L, et al. Clinical significance of epidermal growth factor receptor protein over-expression and gene copy number gains in prostate cancer. Clin Cancer Res 2007; 13 (22 Pt 1): 6579–84PubMedCrossRef
169.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11(1): 21–8PubMedCrossRef
170.
Joensuu G, Joensuu T, Nokisalmi P, et al. A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2010; 78(1): 42–9PubMedCrossRef
171.
Carson 3rd CC, Zincke H, Utz DC, et al. Radical prostatectomy after radiotherapy for prostatic cancer. J Urol 1980; 124(2): 237–9PubMed
172.
Thoms J, Goda J, Zlotta A, et al. Neoadjuvant radiotherapy for locally advanced and high risk prostate cancer: a bigger bang for the buck? Nat Rev Clin Oncol 2011; 8(2): 107–13PubMedCrossRef
Metadata
Title
Pharmacotherapeutic Management of Locally Advanced Prostate Cancer
Current Status
Authors
Dr Jarad M. Martin
Stephane Supiot
Dominik R. Berthold
Publication date
01-05-2011
Publisher
Springer International Publishing
Published in
Drugs / Issue 8/2011
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11591500-000000000-00000

Other articles of this Issue 8/2011

Drugs 8/2011 Go to the issue

Adis Drug Evaluation

Tesamorelin

Adis Drug Profile

Denosumab

Therapy in Practice

Efficacy and Safety of Long-Acting Reversible Contraception

R&D Insight Profile

Ipilimumab

Review Article

End-Organ Protection in Patients with Hypertension

Review Article

New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis